CURRENT ISSUE
September, 2026
No. 111 (9)
2025 Impact Factor: 8.2
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
2025 Journal Citation Indicator: 1.77
2025 CiteScore: 9.7
EDITOR'S PICKS
ARTICLES IN THREE SENTENCES
Article
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy
The choice between non-intensive and intensive chemotherapy (IC) is particularly relevant for young and fit acute myeloid leukemia (AML) patients with non-favorable disease biology. In a prospective multicenter study, Watts and colleagues evaluated venetoclax and azacitidine (ven/aza) in young patients with non-favorable-risk AML and compared their outcomes with matched patients treated with IC. They found that ven/aza achieved better outcomes, while substantially reducing hospitalization, transfusion requirements and infectious complications.
Letter
B-cell precursor acute lymphoblastic leukemia with IGH::CEBP rearrangement: what have we learnt over the years?
IGH::CEBP rearrangements are rare genetic events in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), limiting our understanding of their clinical and biological significance. Alqahtani and colleagues reviewed 151 reported cases of, IGH::CEBP-rearranged BCP-ALL, including six new cases, and analyzed their clinical, cytogenetic and transcriptomic features. IGH::CEBPD was strongly associated with Down syndrome and chromosome 21 gain, while transcriptomic analyses revealed distinct molecular patterns, highlighting the heterogeneous biology of IGH::CEBP-driven BCP-ALL.
Article
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Teclistamab has shown promising activity in heavily pretreated multiple myeloma, but data from routine clinical practice are lacking. Uttervall and colleagues evaluated 113 patients treated with teclistamab in 23 centers. Teclistamab achieved a high overall response rate, durable responses and a median overall survival of 26.3 months, supporting its effectiveness in routine practice despite frequent infections and other immune-related toxicities.
Letter
Extracellular vesicles from aged individuals trigger mitochondrial dysfunction in hematopoietic progenitor cells
Aging impairs hematopoietic stem and progenitor cell function, but the contribution of extracellular vesicles (EV) remains poorly understood. Grenier-Pleau and colleagues investigated the effects of plasma EV from individuals of different ages on human hematopoietic progenitor cells using proteomic, transcriptomic and functional analyses. They showed that EV from older individuals altered gene and protein expression and impaired mitochondrial function, suggesting a role for circulating EV in age-related hematopoietic dysfunction.
TAKE ADVANTAGE FROM HAEMATOLOGICA
